Codeine misuse and dependence in South Africa – learning from substance abuse treatment admissions by Dada, S et al.
RESEARCH
776       September 2015, Vol. 105, No. 9
The global misuse of prescription or over-the-counter 
(OTC) pharmaceutical opioid analgesics, including 
those containing codeine, is an increasing public 
health issue.[1] Misuse is ‘the use of a medicine, with 
or without a doctor’s prescription, clearly outside of 
accepted medical practice or guidelines, for recreational purposes 
or in the framework of self-medication, in greater dosages or for 
longer periods than were prescribed, in which the risks and problems 
associated with use outweigh the benefits’.[2] Dependence refers to a 
diagnosable psychiatric condition.
In response to concerns about the potential misuse of products 
containing (pseudo)ephedrine, the South African (SA) government 
up-scheduled products containing these compounds, which 
now require a doctor’s prescription,[3] despite little evidence that 
OTC medicines containing these substances were purchased to 
manufacture methamphetamine. Similarly, in response to concerns 
about codeine misuse and dependence, some countries such as 
Australia allow codeine only by prescription. SA is considering 
introducing regulations to reduce the amount of codeine in a tablet to 
10 mg and to up-schedule norcodeine and acetylcodeine.[4]
The availability to the public of OTC codeine products has 
compromised efforts to quantify and address hidden codeine 
misuse. Codeine misusers vary: some are dependent on codeine, 
aware of their dependence but using it in response to cravings 
and avoiding withdrawals; some unknowingly misuse codeine by 
using it within the recommended limits, but doing so frequently 
and regularly to treat withdrawal-associated headaches; and some 
deliberately disobey codeine product instructions for intoxication 
purposes. Indicators of the prevalence and incidence of this ‘hidden’ 
form of non-compliant use of habit-forming medicines remain 
scant and rely on individuals who recognise their addiction and 
seek help.[5-8]
We investigated: (i) the extent of treatment demand related to the 
misuse of codeine or codeine dependence in SA; and (ii) the profile 
of patients coming to treatment who are misusing or dependent 
on codeine as part of the comprehensive, multicountry Codeine 
Use, Misuse and Dependence (Codemisused) Study funded by the 
European Union (EU) to inform the design of pharmacy screening and 
brief interventions, risk management, monitoring and surveillance, 
continuing professional development training, and the development 
of specific clinical/community pharmacy treatment protocols.
Methods
The South African Community Epidemiology Network on Drug 
Use (SACENDU), established in 1996, is a network of researchers, 
practitioners and policy makers from all nine provinces in SA who 
meet every 6 months to provide community-level public health 
surveillance information about alcohol and other drug (AOD)-related 
trends.[9] All AOD treatment centres are requested to join the network, 
although participation is voluntary. SACENDU collects data from 66 
treatment centres nationally with an estimated 75% national coverage, 
particularly focusing on the larger treatment centres, including state-
funded, private non-profit and private for-profit facilities. Our data 
were collected from SACENDU participating centres between January 
and December 2014, and 17 260 admissions were recorded.
For monitoring, a standardised form is completed for each 
person treated by a given centre during a 6-month period. 
This records the source of referral for treatment, biographical 
information, the type of treatment received (inpatient and/or 
outpatient), whether the admission was voluntary or not, the 
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primary and secondary substances of abuse 
(including alcohol, OTC and prescription 
medicines and illicit drugs), the mode(s) 
of substance use, frequency of use, age 
of first use, whether treatment had been 
received before the current episode, who 
pays for treatment, and whether they had 
received an HIV test during the past 12 
months. The data collection is completed at 
admission to the treatment centre or shortly 
thereafter. As a result of our participation in 
the Codemisused Study on use, misuse or 
dependence on codeine, specific questions 
were added to the form at the start of 
2014. These focused on the type of codeine 
medication misused or on which the person 
is dependent, the frequency of codeine use, 
non-communicable illnesses from which 
the person suffers, and use of tobacco 
products. The instrument is broadly based 
on that developed by the Pompidou Group 
in Europe and on the treatment demand 
indicators used by the European Monitoring 
Centre for Drugs and Drug Addiction.[10]
Data were analysed using IBM SPSS 
version 22, and mainly comprised descriptive 
statistics and cross-tabulations.
Ethical approval was provided by the South 
African Medical Research Council’s Ethics 
Committee and Stellenbosch University’s 
Health Research Ethics Committee. The 
study was a record review, and consent from 
patients was not required.
Results
In 2014, 435 treatment admissions (2.5% of 
all admissions) involved codeine misuse or 
dependence as a primary or secondary sub-
stance of abuse. Only 137 patients (0.8%) had 
codeine as their primary substance of abuse.
Patient demographics
Of admissions recorded, 124 (29.0% of 
admissions for codeine misuse/dependence) 
were in Gauteng Province, 104 (23.9%) in 
the Eastern Cape and 92 (21.1%) in the 
Western Cape. Other regions reported fewer 
admissions: 56 (12.9%) in the central region 
(Free State, Northern Cape and North West 
provinces), 35 (8.0%) in KwaZulu-Natal, and 
22 (5.1%) in the northern region (Mpumalanga 
and Limpopo provinces). Across the six 
regions/provinces, 14 centres saw two-thirds 
of all patients reporting misuse/dependence 
on codeine as either a primary or secondary 
substance of abuse (Table 1).
Males comprised 74.9% of the patients, of 
whom all except six were SA citizens. The 
youngest in treatment for codeine misuse 
or dependence were 11 years old and the 
oldest was 70 years old. The age category 
with the highest proportion of patients was 
20 - 29 years, followed by 30 - 39 years (Table 
2). Just over 15% were aged ≤19 years, with 
two aged 11, one aged 13, and five aged 14. 
Only 12 were aged ≥60. Almost 60% had a 
high-school education or higher, and 45.5% 
reported being currently employed.
Referral sources, sources of 
payment, current illnesses and 
tobacco use
While over 40% of patients with codeine as 
a primary or secondary substance of abuse 
were referred by self, family and/or friends, 
26.7% were referred by health professionals; 
36.8% had previously received treatment for 
codeine misuse or dependence. The primary 
source of payment was medical aid (43.8%), 
family (16.4%) and self (13.9%). When asked 
about current illnesses, 78.9% of patients 
indicated ‘none’. The most common illness 
reported was mental health problems (5.3%), 
followed by blood pressure problems (4.1%). 
With regard to tobacco use (more than once 
a week), over half of the patients reported 
not using any tobacco, with 4.3% indicating 
at least weekly cigarette use.
Type of codeine, frequency of use 
and whether it was the primary 
substance of abuse
Of the 435 admissions across the SACENDU 
treatment centres, 14 (3.0%) did not contain 
detailed information on the specific product 
containing codeine that was most frequently 
used. Table 3 shows the codeine products 
most frequently reported as being misused. 
Together they comprise 80.7% of the 
medications containing codeine listed. Most 
of the codeine products reported were in 
tablet/capsule form, but 17.6% (n=74) were 
syrups. Most included paracetamol, and 
many also included caffeine.
The codeine was most frequently taken 
through swallowing (96.6%), with 2.5% of 
patients snorting/sniffing, 0.7% smoking 
and 0.2% swallowing/snorting. Most patients 
(63.1%) reported daily use of products 
containing codeine, but 14.3% reported using 
2 - 6 days per week and 11.4% once per week 
or less often; 11.2% reported not having used 
in the past month. Of the patients, 31.7% had 
an OTC or prescription medication as their 
primary drug of abuse (Table 4) and 68.3% 
reported other substances as their primary 
drug of abuse, mainly alcohol, cannabis and 
heroin.
Discussion
In treatment centres participating in 
SACENDU, fewer than 1% of persons had 
codeine as their primary substance of abuse, 
similar to findings in centres participating 
in the National Drug Treatment Moni-
toring System (NDTMS) in the UK in 
2012/13 (1.2%) and in the National Drug 
Treatment Reporting System (NDTRS) in 
Ireland between 2008 and 2012 (0.8%).[11] 
Considering codeine as a primary or secon-
dary substance of abuse, the figure rises to 
2.5% in the 2014 SA data, again similar to 
the NDTMS (2.1%) and NDTRS (1.9%).[11] 
These percentages are low compared with 
alcohol, cannabis, methamphetamine and 
other substances of abuse in SA, but because 
of the large numbers who receive treatment, 
many persons in specialist substance abuse 
treatment centres misuse or are dependent 
on codeine: 435 in SA, 1 548 in Ireland and 
4 065 in the UK.[11]
However, many people who misuse or are 
dependent on codeine do not seek help from 
specialist substance abuse treatment centres, 
instead consulting general practitioners or 
Table 1. Listing by region of centres seeing ten or more patients reporting codeine 
misuse or dependence as a primary or secondary substance of abuse
Province/region
Treatment centres seeing 
≥10 patients, n centres
Range across centres treating 
≥10 patients, n patients
Central region 3 12 - 17
Eastern Cape 3 10 - 78
Gauteng 3 14 - 29
KwaZulu-Natal 1 13
Northern region 1 10
Western Cape 3 10 - 29
Table 2. Codeine misuse/dependence by 
age category
Age category (years) n (%)
≤19 67 (15.5)
20 - 29 157 (36.3)
30 - 39 100 (23.1)
40 - 49 69 (15.9)
50 - 59 28 (6.5)
≥60 12 (2.8)
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other healthcare providers. The vast majority are unlikely to seek or 
be able to access any assistance, as they do not view themselves as 
needing help or as ‘drug addicts’.[12] To obtain a better picture of the 
national prevalence rate for codeine misuse/dependence, the extent 
of patients misusing or dependent on codeine who access a broader 
range of service providers, or who do not access services of any kind, 
must therefore be investigated.
We found that less than a third of persons who came to specialist 
substance abuse treatment centres with codeine-related problems had 
codeine as their primary substance of abuse. In most cases codeine 
use was secondary to other substances of abuse, namely alcohol, 
cannabis, heroin/opiates and methamphetamine. Other studies have 
found a link between codeine and alcohol use.[13] In Australia, at 
times when heroin is not easily available, prescription opioids such 
as morphine are used as an alternative.[13] That codeine may be being 
used as a substitute for heroin in SA when the latter is not available 
warrants further investigation. Use of codeine by methamphetamine 
users has been reported infrequently; a New Zealand study found that 
15.3% in 2008 and 12.2% in 2009 had reported simultaneous use of 
methamphetamine and codeine.[13]
Our finding that three-quarters of persons in treatment reporting 
misuse or dependence on codeine were male and under 40 years of 
age contrasts with international research, where the clinical profiles 
of codeine-dependent persons are over-represented by females and 
those in middle to late age.[13] Given that our sample comprises 
persons seen in specialist drug treatment centres, it is highly likely 
that females and older persons are under-represented in such 
samples, reflecting their experience of barriers to accessing specialist 
substance abuse treatment.[14] The finding that >15% of persons in 
treatment who reported misusing or being dependent on codeine 
were aged ≤19 years, and that these included children as young as 11 
years of age, also warrants further investigation.
In terms of geographical distribution of persons in SA receiving 
specialist substance abuse treatment with codeine as a primary or 
secondary substance of abuse, Gauteng and the Western Cape may 
have been expected to feature prominently because of the number of 
treatment centres and persons in treatment in these provinces. That the 
Eastern Cape had such high numbers of codeine-misusing or dependent 
persons was unexpected. This finding is due to the inclusion of a private 
treatment facility that has recently seen an increase in patients admitted 
for mental health and substance abuse comorbidity. The clinical profile 
of codeine-dependent persons has been found in New Zealand to 
include those with underlying psychiatric condi tions. [13] Some 18% 
of persons reporting codeine as a primary or secondary substance of 
abuse indicated use of syrups containing codeine. This contrasts with 
1.2% in the 2012/13 UK NDTMS dataset and 2.3% in the Irish NDTRS 
dataset,[11] reflecting much easier access to syrups containing codeine in 
SA and suggesting another area for further study and possibly greater 
regulation. Many of the codeine preparations were combined with 
paracetamol, a compound the long- term use of which can cause kidney 
damage.[12] In the UK, boxes containing codeine tablets or capsules have 
a warning not to use them for longer than 3 days, something that should 
perhaps be considered in SA.
Study limitations
Our study has several limitations. Chief among them is that there 
are barriers to accessing treatment and certain population sectors 
Table 3. Codeine products most frequently reported as being misused or causing dependence
Product
Quantity of codeine per 
tablet/capsule, mg Codeine and other components n (%) Rank*
Stilpane 8 Paracetamol, caffeine, meprobamate 124 (28.5) 1
Adco-Dol 10 Paracetamol, caffeine, doxylamine 104 (23.9) 2
Benylin syrup with 
codeine
N/A Diphenhydramine hydrochloride, 
levomenthol
33 (7.6) 3
Myprodol 10 Paracetamol, ibuprofen 19 (4.4) 4
Bronchleer cough syrup N/A Diphenhydramine hydrochloride, 
ammonium chloride, sodium citrate
16 (3.7) 5
Lenazine Forte cough 
syrup
N/A Ephedrine hydrochloride, 
promethazine hydrochloride
11 (2.5) =6
Syndol 10 Paracetamol, caffeine, doxylamine 11 (2.5) =6
Panado-Co 8 Paracetamol, potassium sorbate 10 (2.3) 8
Adco-Sinal CO 15 Paracetamol, phenylpropanolamine 
HCl, phenyltoloxamine citrate
9 (2.0) 9
Acurate 10 Paracetamol, caffeine, doxylamine 7 (1.6) =10
Disprin Plus 8 Aspirin 7 (1.6) =10
NA = not applicable.
*1 = most misused, 10 = least misused.
Table 4. Primary drug of abuse for persons in treatment 
misusing/dependent on codeine
Primary substance of abuse %
OTC/prescription drug 31.7
Alcohol 21.4
Dagga (cannabis) 14.7
Heroin/opiates 10.6
Methamphetamine 8.3
Methcathinone 6.9
Dagga/methaqualone combination 3.0
Crack/cocaine 2.5
Other 1.1
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are less likely to be included, especially females[12] and persons 
from less advantaged communities.[15] It should also be noted that 
the data collection instrument used by SACENDU does not enable 
determination of whether the patient’s use of one or more substances 
has reached the level of dependence as determined by the Diagnostic 
and Statistical Manual, version IV (DSM-IV) or the International 
Classification of Diseases, version 10 (ICD-10). Furthermore, our 
data represent treatment admissions. It is therefore possible that 
some admissions are of the same person, thus inflating the number 
of people treated. A further limitation is that the study is cross-
sectional in nature and cannot offer evidence about how the situation 
might change over time. This is important in guiding policy, and 
the increasing demand for treatment related to codeine misuse and 
dependence found in the UK[11] suggests that it should be studied 
further in SA.
Conclusions
With regard to the intention of the Medicines Control Council and 
the SA National Department of Health to further tighten up on the 
sale of OTC medications containing codeine,[4] our research has 
shown that while there is a low level of treatment demand from 
specialist substance abuse treatment centres related to misuse 
of or dependence on products containing codeine compared 
with other substances of abuse, such misuse or dependence 
is likely to translate to over 400 persons per year.[16] However, 
more information is needed on the prevalence of codeine misuse 
and dependence in SA from other sources of data, including 
community samples.
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